Citi analyst Joanne Wuensch raised the firm’s price target on Zimmer Biomet to $140 from $134 and keeps a Neutral rating on the shares as part of a Q1 earnings preview for the medical technology group. Expectations are “medium-to-high” for solid deliveries, encouraged by new products and pent-up demand, the analyst tells investors in a research note. The firm says that while the group has traded in-line with the market year-to-date, “it doesn’t really tell the current MedTech story.” Citi believes the Q1 reports should set-up the remainder of the year, hurdling tough year-over-year compares, as new products remain in focus. Its top picks remain Boston Scientific (BSX), Irhythm Technologies (IRTC) and Intuitive Surgical (ISRG).
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Zimmer Biomet price target raised to $129 from $120 at Roth MKM
- Zimmer Biomet receives FDA clearance for ROSA Shoulder System
- BTIG medical technology analyst to hold analyst/industry conference call
- Zimmer Biomet Announces Quarterly Dividend for First Quarter of 2024
- Zimmer Biomet signs Global Health Equity Network’s Zero Health Gaps Pledge